Maraviroc, as a switch option, in HIV-1 infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first N(t)RTI+PI/r regimen. Week 48 results of the randomised, multicentre MARaviroc switCH study (MARCH).